Table 4 Model parameters estimated on Phase I participants by Pasin et al.¹⁶ and the new estimates obtained on pooled Phase I and Phase II data and considering adjustment for laboratory effects.

δ_Ab

Antibody decay rate (day⁻¹)

0.029

[0.027; 0.033]

Women

0.0251

[0.0223; 0.0283]

Men

0.0353

[0.0296; 0.0421]

\(\log ({{{2}}})/{{{{\delta }}}}_{{{{\rm{Ab}}}}}\)

Antibody half-life (days)

24

[22; 26]

Women

27.6

[24.5; 31.1]

Men

19.6

[16.4; 23.4]

δ_S

SL ASCs decay rate (day⁻¹)

0.231

[0.15; 0.36]

0.333

[0.326; 0.340]

\(\log ({{{2}}})/{{{{\delta }}}}_{{{{\rm {{S}}}}}}\)

SL ASCs half-life (days)

3.0

[1.9; 4.7]

2.08

[2.04; 2.13]

δ_L

LL ASCs decay rate (year⁻¹)

3.16 × 10⁻⁴

[1.46; 7.03] × 10⁻⁴

1.25 × 10⁻⁴

\(\log ({{{\bf{2}}}})/{{{{\boldsymbol{\delta }}}}}_{{{{\boldsymbol{L}}}}}\)

LL ASCs half-life (years)

6.0

[2.7; 13]

15.0

ϕ_S

SL ASCs influx (EU/mL/day)

2755

[1852; 4100]

Mean Age (31.3 years)

3057

[2418; 3865]

FC ΔAge = + 1 year^a

0.934

[0.915; 0.954]

ϕ_L

LL ASCs influx (EU/mL/day)

African part.

16.6

[13.7; 20.1]

10.2

[9.01; 11.4]

Eur. part.

70.7

[54.0; 92.7]

36.6

[27.3; 49.2]

α

Scaling factor—lab effects

α_focus

1.04

[0.93; 1.16]

α_Q2sol

1.00

[0.98; 1.02]

\({{{{\omega }}}}_{{{{{\phi }}}}_{{{{\rm{S}}}}}}\)

Sd of RE on ϕ_S

0.92

[0.83; 1.01]

0.84

[0.56; 1.13]

\({{{{\omega }}}}_{{{{{\phi }}}}_{{{{\rm{L}}}}}}\)

Sd of RE on ϕ_L

0.85

[0.78; 0.92]

0.88

[0.81; 0.96]

\({{{{\omega }}}}_{{{{{\delta }}}}_{{{{\rm{Ab}}}}}}\)

Sd of RE on δ_Ab

0.30

[0.24; 0.36]

0.35

[0.29; 0.41]

σ_Ab

Sd of error model

0.10

[0.10; 0.10]

0.107

[0.101; 0.112]